山外山 20250708 摘要 国内血液净化行业发展空间广阔，患者数量持续增长，但国产替代率仍 有提升空间，山外山和威高雪净等企业有望受益。 山外山在血液净化设备和耗材方面均具备优势，尤其与瑞士 Dialife 合资 的德莱福透析器，以蒸汽灭菌技术提升产品品质，具有市场竞争力。 山外山积极拓展海外市场，尤其在巴西、俄罗斯及东南亚等地销售增长 迅速，境外收入占比虽小但增速显著，未来有望成为重要增长点。 预计山外山未来三年收入和利润将保持 30%左右的复合增长率，设备销 售仍是主要收入来源，耗材和医疗服务业务稳步增长。 山外山管理团队稳定，创始人高光勇先生为实际控制人，具备核心技术 优势，多次参与国家技术标准制定，增强了公司在血液净化领域的竞争 力。 政策推动国产替代，集采降价对山外山出厂价影响较小，公司通过技术 创新和全线产品布局，提升市场竞争力，并积极发展血液透析服务。 综合考虑行业前景、产品竞争力、海外业务增长潜力及估值水平，认为 山外山具备长期投资价值，当前是观察并投资的良好时机。 Q&A 山外山在国内血液净化领域的地位如何？ 山外山是国内血液净化领域的龙头企业，无论是在设备还是耗材方面都具有领 先地位。 ...

转自：前瞻产业研究院 1、深圳市高端医疗器械产业政策环境 ——深圳市高端医疗器械产业重点政策梳理 深圳作为中国改革开放的标杆城市，其政策红利的持续释放与创新迭代，使其成为全球投资者不可忽视 的战略高地。深圳从"政策红利"向"产业红利"转型的核心抓手是科技创新，始终以产业需求为导向，推 动产业结构向高端化、智能化跃迁。 作为全球和中国高端医疗器械产业的核心阵地，深圳的政策红利的精准性、系统性和前瞻性，使其成为 资本与技术汇聚的"超级磁场"。 近年来，深圳市出台多项鼓励性政策，不断加大对高端医疗器械产业的支持力度。2024年3月，深圳出 台《关于加快发展新质生产力进一步推进战略性新兴产业集群和未来产业高质量发展的实施方案》，指 出针对具有战略意义、处于风口期、资源投入大的高端医疗器械等7个产业集群，举全市之力集聚资 源，以超常规力度支持培育。 | 时间 | 政策名称 | 内容解读 | | --- | --- | --- | | 2025年4月 | 《深圳市全链条支持医药 和医疗器械发展若干措 | 聚焦高端医学影像、医用机器人、高性能植介入器械、体外诊断、生命监护 | | | | 与支持、人工智能辅助诊断系统等方向 ...

中信建投研报称，中长期来看，医疗器械行业的产业趋势向好，创新、并购、国际化将推动中国器械龙 头逐步成长为全球龙头。预计三季度多家公司受益新产品新业务放量而实现环比改善，或去年同期低基 数基础上实现高增长。细分板块来看，医疗设备板块部分企业受益于行业招标数据高增长和库存加速消 化、业绩将逐步改善，高值耗材板块部分企业有望受益新产品逐步放量和集采优化政策、业绩确定性和 估值修复。也看好脑机接口、外骨骼机器人、AI医疗、手术机器人等新科技方向的投资机会。 中金公司：预计新消费标的延续相对高成长 健康饮品等新消费趋势景气度有望保持 凤凰网财经讯 7月9日，三大指数开盘涨跌不一，沪指高开0.04%，深成指高开0.04%，创业板指低开 0.08%。托育、机器人等板块指数涨幅居前，贵金属、保险等板块指数跌幅居前。 | | | | | | 沪深京重要指数 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | *● | 咸新 | 涨幅% | | 涨跌 涨跌家数 | | | 现手 | 金额 | | 上证指数 | | 3498. ...

内容概要：随着中国经济的发展，人们的生活水平不断提高，更多的人开始重视健康和运动，他们会更 多地投入到健身运动中，这使得肌内效贴布的需求稳步上升。特别是在运动员和健身爱好者中，肌内效 贴布凭借透气性、舒适性、缓解疼痛、支持、放松软组织等优点，逐渐成为人们日常运动装备的一部 分。此外，随着老龄化速度的加快，越来越多的老年人开始关注肌内效贴布，尤其是在缓解关节和肌肉 疼痛方面，功能性贴布的需求不断增加，进一步推动肌内效贴布行业规模增长。据统计，2024年中国肌 内效贴布行业市场规模达到19.9亿元，同比上涨15.0%。 肌内效贴布是一种带有弹性的超薄透气胶带，有不同的宽度、颜色和弹性，可以根据需要剪切成不同的 形状，贴在需要治疗的皮肤、肌肉和关节上。与传统的膏药或药布相比，它极大减少皮肤过敏或适应不 良的情形，且允许治疗部位自然活动。肌内效贴布于20世纪70年代起源于日本，发展于欧美，而国内对 肌内效贴布的认识则始于北京奥运会。经推广，现该技术不仅用于各类运动损伤的处理，且广泛延伸到 临床康复等领域。目前，肌内效贴布主要有三个方面的治疗作用：①缓解疼痛；②改善循环，减轻水 肿；③支持、放松软组织，改善不正确的动作 ...

Core Viewpoint - China has implemented restrictions on medical device procurement from European companies in response to similar measures taken by the EU against Chinese firms, indicating a tit-for-tat approach in trade relations [1][5]. Group 1: Government Procurement Measures - The Ministry of Finance announced that for medical device procurement budgets exceeding 45 million RMB, EU companies will be excluded from participation, except for EU-funded enterprises operating in China [2][4]. - The measures specifically target 50 types of medical devices imported from the EU, including both everyday medical instruments and high-end equipment like MRI and X-ray diagnostic devices [4][6]. Group 2: Impact on Domestic Industry - The restrictions are expected to significantly impact high-end medical device manufacturers from the EU, while domestic companies are increasingly filling the market gap with competitive products [5][6]. - Currently, imported medical devices account for 40% of a typical domestic company's business, with only 10% coming from the EU, indicating a shift towards non-EU suppliers [4][6]. Group 3: Future Trends in Domestic Medical Device Market - The domestic medical device industry is projected to see an increase in the replacement rate of imported products, with estimates suggesting that 60% to 80% of devices priced around 5 million RMB can be sourced domestically [7][8]. - The market for high-end medical devices is expected to grow significantly, with projections indicating that by the end of the 14th Five-Year Plan, the market size could reach approximately 2.27 trillion RMB, accounting for 28% of the global market [8][9].

祥生医疗（证券代码：688358）发布2024年年度权益分派实施公告。公司拟向全体股东每10股派发现金 红利10元（含税），总股本112,124,537股，扣除回购专用证券账户中股份数249,784股后的股本 111,874,753股为基数，合计拟派发现金红利111,874,753.00元（含税），占公司当年度合并报表归属上 市公司股东净利润的比例为79.62%。本次分红不进行资本公积转增股本，不送红股。股权登记日为 2025年7月14日，除权（息）日和现金红利发放日均为2025年7月15日。根据相关规定，公司按照以下公 式计算除权（息）参考价格：除权（息）参考价格=（前收盘价格-现金红利）÷（1+流通股份变动比 例）。虚拟分派的每股现金红利约为0.9978元/股。无限售条件流通股的红利委托中国结算上海分公司 派发，部分股东红利由公司自行发放。对于不同类型的股东，公司根据相关法律法规代扣代缴相应的所 得税。如有疑问，请联系证券事务部，联系电话：0510-85271380。 上海市通力律师事务所关于无锡祥生医疗科技股份有限公司差异化分红事项之专项法律意见书 上海市通力律师事务所接受祥生医疗委托，就2024年度利 ...

董秘最新回复 截至2025年7月8日收盘，美好医疗(301363)报收于18.17元，下跌0.27%，换手率5.0%，成交量7.81万 手，成交额1.41亿元。 投资者： 董秘您好，1、在2024年年报的行业发展趋势里提到产业技术加快，运用生物、微纳米、信 息、计算机、微加工等高新技术，发展用于微创或无创诊疗的技术和器件，表面改性和组织诱导性生物 医用材料及组织和器官修复器械，以及用于医院及远程诊疗的信息系统。请问贵司产品使用了当下哪些 新技术？2、医疗器械产品向智能化方向转变。请问贵司产品如何体现智能化的应用，比如是否使用机 器人、传感器等提高效率？ 董秘： 尊敬的投资者，您好！公司已预约于2025年8月19日披露2025年半年度报告。感谢您对公司的关 注！ 当日关注点 交易信息汇总：7月8日主力资金净流出706.11万元，而散户资金净流入591.99万元。 交易信息汇总 董秘： 尊敬的投资者，您好！技术应用方面。公司构建了基于通用技术模块化复用与专用技术纵深攻 关的开放式研发创新平台。一方面，基于长期服务全球医疗器械头部客户积累的技术基础，公司研发团 队将医疗器械组件及产品的开发技术、塑胶和液态硅胶精密模 ...

Core Points - The document outlines the procedures and regulations for the resignation of directors and senior management at Yingke Medical Technology Co., Ltd, aiming to maintain corporate governance stability and protect the rights of the company and its shareholders [1][2]. Chapter Summaries Chapter 1: General Provisions - The regulations are established based on relevant laws and the company's articles of association to standardize the resignation process of directors and senior management [1]. Chapter 2: Resignation Circumstances and Procedures - Directors can resign before their term ends by submitting a written resignation report, which becomes effective upon receipt by the company, and the company must disclose this within two trading days [2]. - If a director resigns and it results in the board falling below the legal minimum number of members, the director must continue to fulfill their duties until a new director is appointed [2]. - The company must complete the election of a new director within sixty days after a resignation to ensure compliance with legal and regulatory requirements [2]. - Senior management can also resign before their term ends, with specific procedures outlined in their labor contracts [2]. Chapter 3: Handover Procedures and Obligations - Resigning directors and senior management must complete handover procedures within five working days after their resignation, including transferring company seals and all relevant documents [3]. - If there are outstanding public commitments, the company can require a written fulfillment plan from the resigning personnel [3]. Chapter 4: Management of Shares Held by Resigning Directors and Senior Management - Resigning directors and senior management are prohibited from transferring their shares within six months of resignation [4]. - There are restrictions on the amount of shares that can be sold during their term and after resignation, ensuring compliance with relevant regulations [4]. Chapter 5: Accountability Mechanism - The board will review and determine accountability measures if a resigning director or senior management fails to fulfill commitments or obligations [5]. - Individuals can appeal the board's decisions regarding accountability within fifteen days [5]. Chapter 6: Supplementary Provisions - Any matters not covered by these regulations or conflicting with national laws will be governed by the relevant laws and the company's articles of association [6].

英科医疗科技股份有限公司 章 程 二〇二五年七月 目 录 第一章 总 则 第一条 为维护公司、股东、职工和债权人的合法权益，规范公司的组织和 行为，根据《中华人民共和国公司法》（以下简称《公司法》）、《中华人民共 和国证券法》（以下简称《证券法》）和其他有关规定，制定本章程。 第二条 公司系依照《公司法》和其他有关规定成立的股份有限公司（以下 简称"公司"）。 公司由淄博英科医疗制品有限公司以整体变更方式设立，在淄博市市场监督 管理局注册登记并取得《营业执照》，统一社会信用代码：9137030068946500X7。 第三条 公司于 2017 年 6 月 23 日经中国证券监督管理委员会（以下简称 "中国证监会"）核准，首次向社会公众发行人民币普通股 2,430.9827 万股，于 第四条 公司注册名称：英科医疗科技股份有限公司 公司英文名称： INTCO MEDICAL TECHNOLOGY CO.,LTD. 第五条 公司住所：淄博市临淄区齐鲁化学工业园清田路 18 号 邮政编码：255414 第六条 公司注册资本为人民币 64,170.0369 万元。 第七条 公司为永久存续的股份有限公司。 第八条 董事 ...

Core Viewpoint - The company has established a comprehensive information disclosure system to ensure compliance with legal requirements and protect shareholders' rights, emphasizing the importance of timely, accurate, and complete information dissemination [1][2][3]. Group 1: Information Disclosure Principles - Information disclosure is a continuous responsibility of the company, which must adhere to relevant laws and regulations [2]. - The company must treat all shareholders fairly and disclose information that may significantly impact their decisions in a clear and understandable manner [3][4]. - The company is required to disclose information proactively, especially if it could materially affect shareholders and stakeholders [3][4]. Group 2: Reporting Requirements - The company must disclose periodic reports, including annual, semi-annual, and quarterly reports, within specified timeframes [5][6]. - If the company anticipates that its annual performance or financial status will significantly change, it must issue a performance forecast within one month after the fiscal year ends [6][7]. - The company must also disclose any major events or transactions that could impact its stock price or investment decisions promptly [8][9]. Group 3: Major Transactions and Related Party Transactions - Major transactions, such as asset purchases or sales, must be disclosed if they meet certain thresholds, including a 10% impact on total assets or significant revenue contributions [10][11]. - Related party transactions must also be disclosed if they exceed specified monetary thresholds, ensuring transparency in dealings with affiliated entities [12][13]. Group 4: Other Significant Events - The company must disclose any significant events that could materially affect its securities or investment decisions, including major losses, legal issues, or changes in management [14][15]. - The company is required to report any changes in its operational status or significant external factors that could impact its business [15][16]. Group 5: Information Disclosure Management - The board of directors is responsible for overseeing the information disclosure process, with the chairman being the ultimate responsible party [17][18]. - The company must maintain a structured approach to information disclosure, ensuring that all relevant personnel are informed and comply with disclosure obligations [19][20]. - The company must implement internal controls to ensure the accuracy and timeliness of financial reporting and disclosures [21][22].